Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study)

NCT02462486 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT02462486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02462486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study)
Lead sponsor
Allergan
Phase
Phase 3
Overall status
Completed
Start date
June 25, 2015
Completion date
June 6, 2019
Enrollment
949 (actual)
Sites
187

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration